Small molecules as RNA-binding protein inhibitors Innovative Azetidine-Based Small Molecules
Medizin
Forschungs-Reagenzien
Nukleinsäure-, Protein-, Zell-bezogene Technologien
Ref.-Nr.: 0803-6519-IKF
Technology
Researchers from the Chemical Genomics Center of the Max-Planck Society have developed a platform for constructing RNA-binding molecules centered on the azetidine core scaffold. By attaching specific aromatic RNA-binding fragments to the azetidine core, these compounds expand the chemical space, enabling customizable libraries and the development of therapeutically relevant molecules.
The key advantages of this method include:
- Innovative Chemical Space: Expands beyond conventional scaffolds with the azetidine core, unlocking novel RNA-binding possibilities.
- High Customizability: Flexible attachment of RNA-binding fragments tailored for specific applications.
- Enhanced Efficacy: Demonstrated potential to improve RNA-binding selectivity and potency.
Broad Applicability: Suitable for drug development in oncology, virology, and neurodegeneration.

Figure 1 Schematic illustration of a small molecule with an azetidine core binding the RNA and inhibition RNA maturation and expression
Patent Information
Patent Application PCT/EP2023078937, filed on October 18, 2023
Opportunity
We welcome research partnerships and licensing to advance this method toward clinical application and are interested in developing novel RNA-targeting therapies that offer improved safety profiles and efficacy.
PDF Download
- Ref.-Nr.: 0803-6519-IKF (252,7 KiB)
Kontaktperson

Senior Patent- und Lizenzmanagerin
Dr. Ingrid Kapser-Fischer
Ernährungswissenschaftlerin, M.Sc.
Telefon: 089 / 29 09 19-19
E-Mail:
kapser-fischer@max-planck-innovation.de